Antibodies News and Research

RSS
Current progress in SARS-CoV-2 vaccine candidates

Current progress in SARS-CoV-2 vaccine candidates

The relative dynamics of infection with the Delta and Omicron SARS-CoV-2 variants in aged and young Syrian hamsters

The relative dynamics of infection with the Delta and Omicron SARS-CoV-2 variants in aged and young Syrian hamsters

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Study examines whether knowledge of virus-neutralizing antibody titer impacted wellness decision-making

Study examines whether knowledge of virus-neutralizing antibody titer impacted wellness decision-making

Patients divided over Alzheimer’s drug: Is it a ‘risk I’m willing to take’ or just a ‘magic pill’?

Patients divided over Alzheimer’s drug: Is it a ‘risk I’m willing to take’ or just a ‘magic pill’?

Binding efficacy of SARS-CoV-2 S1 specific salivary antibodies to the Omicron and Delta variants

Binding efficacy of SARS-CoV-2 S1 specific salivary antibodies to the Omicron and Delta variants

Canopy Biosciences launches next-generation ChipCytometry™ instrument for spatial biology with sub-cellular resolution

Canopy Biosciences launches next-generation ChipCytometry™ instrument for spatial biology with sub-cellular resolution

Combating COVID cytokine storm with targeted nucleic acid therapies

Combating COVID cytokine storm with targeted nucleic acid therapies

CD4 T-cell immunity active six months into COVID-19 convalescence

CD4 T-cell immunity active six months into COVID-19 convalescence

Third dose of COVID mRNA vaccine safe and effective in kidney transplant patients

Third dose of COVID mRNA vaccine safe and effective in kidney transplant patients

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Longitudinal analysis of CD4+ T cells and antibody responses to common cold coronaviruses

Longitudinal analysis of CD4+ T cells and antibody responses to common cold coronaviruses

Effectiveness of mRNA vaccines, antibody treatment reduced by all three omicron subvariants

Effectiveness of mRNA vaccines, antibody treatment reduced by all three omicron subvariants

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Angiotensin-converting enzyme 2-based mutant decoy effectively reduces COVID-19 in mice

Angiotensin-converting enzyme 2-based mutant decoy effectively reduces COVID-19 in mice

Clinical trial report endorses nitazoxanide as a safe drug for moderately ill COVID-19 patients

Clinical trial report endorses nitazoxanide as a safe drug for moderately ill COVID-19 patients

Convalescent plasma therapy shows no significant impact on COVID-19 recovery and outcomes

Convalescent plasma therapy shows no significant impact on COVID-19 recovery and outcomes

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Infection with Omicron sub-lineage BA.1 protects from reinfection against BA.2 sub-lineage and vice-versa

Infection with Omicron sub-lineage BA.1 protects from reinfection against BA.2 sub-lineage and vice-versa

Additional doses of covid-19 vaccine recommended for immunocompromised patients

Additional doses of covid-19 vaccine recommended for immunocompromised patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.